A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma

Table 1 Clinical information of 495 LUSC samples in the TCGA database

Feature	Train cohort (n = 248)		Test cohort (n = 247)		Entire TCGA-LUSC cohort (n = 495)
Feature	n	%	n	%	n	%
Age
<=65	88	35.48	101	40.89	189	38.18
>65	158	63.71	142	57.49	300	60.61
Unknow	2	0.81	4	1.62	6	1.21
Status
Alive	140	56.45	145	58.70	285	57.58
Dead	108	43.55	102	41.30	210	42.42
Gender		0.00
Female	59	23.79	70	28.34	129	26.06
Male	189	76.21	177	71.66	366	73.94
Stage				0.00
Stage I	130	52.42	111	44.94	241	48.69
Stage II	75	30.24	85	34.41	160	32.32
Stage III	37	14.92	46	18.62	83	16.77
Stage VI	4	1.61	3	1.21	7	1.41
Unknow	2	0.81	2	0.81	4	0.81
T stage
T1	57	22.98	57	23.08	114	23.03
T2	146	58.87	142	57.49	288	58.18
T3	33	13.31	37	14.98	70	14.14
T4	12	4.84	11	4.45	23	4.65
M stage
M0	206	83.06	201	81.38	407	82.22
M1	4	1.61	3	1.21	7	1.41
Unknow	38	15.32	43	17.41	81	16.36
N stage
N0	168	67.74	148	59.92	316	63.84
N1	55	22.18	73	29.55	128	25.86
N2	20	8.06	20	8.10	40	8.08
N3	1	0.40	4	1.62	5	1.01
Unknow	4	1.61	2	0.81	6	1.21

ISSN: 1471-2407